Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

Corey A Carter; Aiste Degesys; Bryan Oronsky; Jan Scicinski; Scott Z Caroen; Arnold L Oronsky; Tony Reid; Pedro Cabrales; Joe Roswarski

doi:10.1159/000441775

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

Case Rep Oncol. 2015 Oct 30;8(3):461-5. doi: 10.1159/000441775. eCollection 2015 Sep-Dec.

Authors

Corey A Carter¹, Aiste Degesys¹, Bryan Oronsky², Jan Scicinski², Scott Z Caroen², Arnold L Oronsky³, Tony Reid⁴, Pedro Cabrales⁵, Joe Roswarski¹

Affiliations

¹ Walter Reed National Military Medical Center, Bethesda, Md., USA.
² EpicentRx, Inc., Mountain View, Calif., USA.
³ InterWest Partners, Menlo Park, Calif., USA.
⁴ Moores Cancer Center, University of California, La Jolla, Calif., USA.
⁵ Department of Bioengineering, University of California, La Jolla, Calif., USA.

Abstract

Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms defined by the presence of cells with secretory granules and the potential to produce and release high levels of vasoactive peptides into the circulation, leading to severe flushing and diarrhea, which may adversely affect quality of life. This report presents the case of a 64-year-old man with chronic refractory diarrhea due to pulmonary NET treated with the experimental anticancer agent RRx-001 in a phase II trial called TRIPLE THREAT with subsequent resolution of his diarrhea.

Keywords: Carcinoid syndrome; Epigenetics; Neuroendocrine tumor.

Publication types

Case Reports